Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.32 USD
Change Today -0.04 / -1.69%
Volume 1.0M
SYN On Other Exchanges
Symbol
Exchange
Berlin
NYSE Amex
As of 4:15 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

synthetic biologics inc (SYN) Snapshot

Open
$2.37
Previous Close
$2.36
Day High
$2.43
Day Low
$2.25
52 Week High
03/11/15 - $3.18
52 Week Low
05/14/14 - $1.16
Market Cap
168.7M
Average Volume 10 Days
2.0M
EPS TTM
$-0.32
Shares Outstanding
72.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTHETIC BIOLOGICS INC (SYN)

synthetic biologics inc (SYN) Related Bloomberg News

View More Bloomberg News

synthetic biologics inc (SYN) Related Businessweek News

No Related Businessweek News Found

synthetic biologics inc (SYN) Details

Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company’s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.

17 Employees
Last Reported Date: 03/16/15
Founded in 2001

synthetic biologics inc (SYN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $348.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $298.0K
Compensation as of Fiscal Year 2013.

synthetic biologics inc (SYN) Key Developments

Synthetic Biologics Announces Positive Pharmacokinetics Data from Phase 1a and 1b Trials of SYN-004 to Protect the Microbiome and Prevent C. difficile Infection

Synthetic Biologics Inc. announced positive pharmacokinetics (PK) results from both the Phase 1a and 1b studies of SYN-004, which is being developed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection. The Phase 1a, single-ascending dose PK study provided data to support Synthetic Biologics' hypothesis that SYN-004 taken orally was not systemically available in the dose range tested. The PK data from this study measured blood levels of a single dose of SYN-004 in participants over a 10-fold dose range. Minimal levels of SYN-004 were observed in the bloodstream across the dose range investigated in the participants. The Phase 1b, multiple-ascending dose PK study provided data to further support that SYN-004 is not systemically available, as no meaningful levels of SYN-004 were observed in the bloodstream after participants received multiple doses of SYN-004 four times a day over a seven-day period. The PK data confirm Synthetic Biologics' expectations based on previous data from the first generation enzyme (P1A). In addition, no clinically significant safety events were observed, and both the single and multiple doses of SYN-004 were well tolerated by the participants of the Phase 1 studies. Synthetic Biologics intends to continue the clinical development of SYN-004 in a Phase 2a clinical trial to evaluate the ability of SYN-004 to degrade residual IV antibiotic in the gastrointestinal (GI) tract, therefore potentially protecting the gut microbiome and preventing C. difficile infection.

Synthetic Biologics Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Operational Update

Synthetic Biologics Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported loss from operations was $20,502,000 against $12,339,000 for the same period last year. Net loss was $19,784,000 or $0.32 basic and diluted per share against $12,318,000 or $0.27 basic and diluted per share for the same period last year. Net loss attributable to company and subsidiaries was $19,784,000 or $0.32 per basic and diluted share against $12,317,000 or $0.27 per basic and diluted share for the same period last year. The company provided an operational update. SYN-004 is a first-in-class oral enzyme preventive therapy designed to protect the gut microbiome from the unintended harmful effects of intravenous (IV) antibiotics, for the prevention of C. difficile infection. SYN-010 is a proprietary, modified-release statin formulation optimal for reducing methane-production by certain microorganisms in the gut to treat the underlying cause of pain, bloating, and constipation associated with IBS-C. SYN-005 is a novel combination of two monoclonal antibodies designed to treat Pertussis (whooping cough) by targeting and neutralizing pertussis toxin. TrimestaTM (oral estriol) may offer a differentiated mechanism of action in the treatment of RRMS, as demonstrated in clinical trials. Based on Phase 2 clinical findings, Trimesta may offer both anti-inflammatory (decrease in relapse rate) and neuroprotective (improvements in disability and cognition) benefits for patients with MS when taken in combination with Copaxone®.

Synthetic Biologics, Inc. to Present Preclinical Results Supporting the Development of the Therapy SYN-004 at Health Conference

Synthetic Biologics reported that preclinical results supporting the development of the therapy SYN-004, SYN's candidate therapy to degrade intravenous antibiotics within the gastrointestinal tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, will be presented during Digestive Disease Week 2015 in Washington, D.C. on May 19. SYN said that SYN-004 continues to gain visibility and recognition among academic peers, and that SYN plans to initiate a Phase 2a clinical trial of SYN-004 in first quarter, with a Phase 2b clinical trial slated for the second half of 2015. SYN said the U.S. Centers for Disease Control and Prevention has categorized C. difficile as an urgent public health threat, and noted that there are 1.1 million C. difficile infections and 30,000 C. difficile-related deaths in the United States each year. SYN said that about118 million doses of antibiotics could be inactivated in the GI tract by SYN-004, annually.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SYN:US $2.32 USD -0.04

SYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SYN.
View Industry Companies
 

Industry Analysis

SYN

Industry Average

Valuation SYN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 17.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTHETIC BIOLOGICS INC, please visit www.syntheticbiologics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.